Adipose gene expression profiles related to metabolic syndrome using microarray analyses in two different models

Diabetes and Metabolism Journal

Volumn 38, Issue 5, 2014, Pages 356-365

  Yoo, Hye Jin ^a   Hwang, Hwan Jin ^a   Jung, Tae Woo ^a   Ryu, Ja Young ^a   Hong, Ho Cheol ^a   Choi, Hae Yoon ^a   Baik, Sei Hyun ^a   Choi, Kyung Mook ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Lipocalin 2; Microarray; PPAR gamma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; FATTY ACID BINDING PROTEIN 4; GLUCOSE; INTERLEUKIN 6; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAABDOMINAL FAT; LEUKOCYTE COUNT; LIPOCALIN 2 GENE; LONG EVANS TOKUSHIMA OTSUKA RAT; MALE; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; UREA NITROGEN BLOOD LEVEL;

EID: 84908876846     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2014.38.5.356     Document Type: Article

References (29)

1. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator- activated receptor agonists. Diabetes 2005; 54:2460-70.
2. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89:463-78.
3. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43:661-6.
4. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26:172-8.
5. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51:314-7.
6. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007; 18:18-25.
7. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422-8.
8. Kawano K, Hirashima T, Mori S, Natori T. OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 1994;24 Suppl:S317-20.
9. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005; 102:10610-5.
10. Chen D, Wang MW. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005; 7:307-17.
11. Shima K, Zhu M, Mizuno A. Pathoetiology and prevention of NIDDM lessons from the OLETF rat. J Med Invest 1999;46:121-9.
12. Sun G. Application of DNA microarrays in the study of human obesity and type 2 diabetes. OMICS 2007; 11:25-40.
13. Draghici S, Khatri P, Eklund AC, Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006; 22:101-9.
14. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006; 7:55-65.
15. Jayapal M, Melendez AJ. DNA microarray technology for target identification and validation. Clin Exp Pharmacol Physiol 2006; 33:496-503.
16. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34-41.
17. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84:491-5.
18. Bassett J; International Diabetes Institute; World Health Organization; Regional Office for the Western Pacific; International Association for the Study of Obesity; International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Australia: Health Communications Australia; 2000.
19. Gusnanto A, Calza S, Pawitan Y. Identification of differentially expressed genes and false discovery rate in microarray studies. Curr Opin Lipidol 2007; 18:187-93.
20. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008;158:203-7.
21. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436:356-62.
22. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-12.
23. Kjeldsen L, Cowland JB, Borregaard N. Human neutrophil gelatinase- associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 2000; 1482:272-83.
24. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006; 19:211-5.
25. Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol 2008; 22:1416-26.
26. Yan QW, Yang Q, Mody N, Graham TE, Hsu CH, Xu Z, Houstis NE, Kahn BB, Rosen ED. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007;56:2533-40.
27. Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, Windham GB, Ble A, Senin U, Ferrucci L. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2007; 49:1841-50.
28. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
29. Das UN. Metabolic syndrome X: an inflammatory condition Curr Hypertens Rep 2004;6:66-73.